Why track record and translational fluency matter more than capacity alone
Author: Hady Shahin, PhD, Scientist, NorthX Biologics
In 2014, a child with leukaemia received the first CAR-T cells to enter a clinical trial in Europe. The infusion did not happen in a sprawling pharmaceutical hub. It happened at Karolinska Institute, in Stockholm, where a small GMP unit had already produced Sweden’s first gene therapy drug for clinical trials back in 1997, when most of the industry was still debating whether any of this was possible. That is the paradox at the heart of the advanced therapy medicinal products (ATMP) story. The science arrived before the infrastructure, the clinical results before the commercial frameworks, and the patients before the supply chains capable of reliably reaching them.
ATMPs are no longer the new kid on the biologics block. They have matured faster than anyone anticipated and now demand to be taken seriously on their own terms, not as a category of therapeutic promise, but as an industrialising reality with its own manufacturing economics, regulatory architecture, and commercial logic.
The numbers speak plainly. The cell therapy biomanufacturing market, valued at USD8.46 billion in 2025, is projected to reach USD 24.6 billion by 2032, nearly tripling in seven years. This growth is not being driven by speculative pipelines, but by therapies already in clinical use across oncology, immunology, tissue restoration, and rare disease, indications where, for some patients, these therapies represent the only remaining option. More telling still is where the growth is concentrating. The ATMP CDMO segment is projected to grow from USD 9.3 billion to USD 31.1 billion over the same period, outpacing the broader market [i] That divergence is not a coincidence. It reflects a simple reality: manufacturing these therapies reliably at scale requires specialised expertise that most developers cannot build in-house. The organisations that hold that capability are becoming structurally indispensable.
By the end of 2024, around 20 ATMPs had received marketing authorisation in Europe, with the EU hosting hundreds of active clinical trials in 2023, a substantial share of global activity. Europe is not merely participating in this field. It is, in significant part, where the field was built. Off-the-shelf allogeneic therapies are the next inflection point, not as a convenience, but as a clinical and commercial necessity. The question is no longer whether they will define the next decade of cell therapy.It is whether the manufacturing infrastructure exists to deliver on that obligation.
Beyond the binary: why allogeneic is the stronger bet at scale
Autologous cell therapies did something remarkable. They proved that engineered cells could hunt and kill cancer inside a living human being. That achievement should not be trivialised. But proof of concept is not a platform. And the architecture of autologous manufacturing, one donor/patient, one batch was never designed to reach the millions of patients who will need these therapies as indications broaden.
The arithmetic of allogeneic manufacturing is simply more compelling. A single healthy donor-derived master cell bank, or a clonal iPSC line, can generate many hundrads of doses in one manufacturing run. Batch production replaces bespoke logistics. Centralised QC release replaces operational complexity. Inventory models become feasible. In autologous manufacturing, cost is structurally embedded in the one-patient, one-batch model and remains inherently difficult to reduce. In allogeneic manufacturing, cost is still substantial, but it becomes something that can be engineered down through scale, standardisation, and process optimisation.
Then there is the clinical argument that rarely appears in the commercial literature: time is itself a therapeutic variable. In aggressive haematological malignancies like acute myeloid leukemia, a patient cannot wait weeks for a bespoke product to be manufactured, released, and shipped. Disease does not hold. An immediately available off-the-shelf product is not merely a logistical convenience; in some indications it is the difference between a patient who receives treatment and one who deteriorates past eligibility before the vial arrives.
Autologous modalities are also, fundamentally, a geography problem. Autologous manufacturing is for the most part tethered to major academic centres with authorised tissue establishments, chain-of-identity infrastructure, and specialist teams to manage them. Frozen allogeneic inventory, by contrast, is a supply model compatible with the actual geography of disease, which is to say, everywhere.
The remaining scientific challenge is real and should not be papered over: immune rejection. Allogeneic cells are foreign, and the host immune system is not indifferent to that fact. But this is precisely where the field’s most consequential engineering is now concentrated. Hypoimmunogenic ATMPs, cells deliberately engineered to evade host immune surveillance through knockout of MHC class I and II expression, insertion of tolerogenic signals, or iPSC-derived universal donor platforms, represent a credible path through this barrier. Not around it.
From promise to patient: allogeneic ATMPs in the clinic
The clinical picture in Europe is still forming, but the contours are clear enough to read. Allogeneic ATMPs have produced results worth noting, not as proof of concept, which is already substantially established, but as early signals of what scale might eventually look like.
In oncology, our partner, Mendus, a Dutch/Swedish company whose lead platform vididencel is an allogeneic, off-the-shelf dendritic cell-based immunotherapy, is developing the product as a maintenance therapy for Acute Myeloid Leukemia (AML). Vididencel is designed to stimulate active immunity against residual cancer cells, with the goal of improving disease-free and overall survival in patients who are in first complete remission following first-line chemotherapy. The programme addresses one of the disease’s most persistent clinical problems: roughly half of AML patients who achieve complete remission eventually relapse, driven by residual cancer cells that survive initial chemotherapy. In the ADVANCE II study, long-term proof-of-concept data show durable remissions and confirm vididencel’s mechanism as an active immunotherapy: at 48 months of median follow-up, 13 of 20 patients remain alive, and 5 have surpassed five-year survival.
As Mendus’s manufacturing partner, we have played a central role in the vididencel programme, producing GMP batches in support of Phase 3 readiness. The collaboration began early, which proved fundamental: facility upgrades were tailored to the specific requirements of an allogeneic dendritic cell vaccine, and that groundwork enabled a successful fast technology transfer of both the manufacturing process and its associated analytical methods.
The recent expansion into Chronic Myeloid Leukemia ( CML) follows the same immunological premise. Tyrosine kinase inhibitors (TKI) have transformed CML into a manageable chronic condition, but most patients require lifelong therapy, with associated toxicity and cost. Mendus has announced the start of the VITAL-CML trial, a Phase 1b study evaluating vididencel in patients with chronic-phase CML who have a sub-optimal response to TKIs, with the longer-term aim of helping more patients achieve treatment-free remission[ii]. The ambition is not to replace the standard of care, but to cure.
The second area of emerging signal is the pivot toward autoimmune disease, where the allogeneic argument is operationally compelling for different reasons. Early results are modest in scale. They are also directionally encouraging. A small pilot study of allogeneic anti-CD19 CAR T cells in four patients with refractory systemic lupus erythematosus demonstrated clinical remission, with one patient discontinuing most immunosuppressive therapy and achieving a low-dose or medication-free remission state at several months, alongside profound B cell depletion within weeks. In myositis and systemic sclerosis, early case series show that allogeneic CAR T cells can persist for several months, induce complete B cell depletion within two weeks, and be associated with clinical improvement and reduced B cell infiltration in skin tissue, with no serious adverse events reported through six months of follow-up[iii]–[iv]. Autoimmune diseases are estimated to affect between five and ten percent of the global population, and Europe, with its ageing demographics and high diagnostic rates, sits toward the upper end of that range. At that prevalence, fully bespoke autologous manufacturing would be difficult to scale.
The clinical signals are encouraging. But a therapy’s clinical logic and its manufacturing logic are not the same argument, and the distance between them is where programmes most reliably fail.
Lost in translation: why the gap between research logic and GMP logic is where cell therapy programmes go to fail quietly
What makes or breaks ATMP programmes is not primarily access to funds, though in this environment, capital is never far from the conversation. The reason for ATMP failure is structural. It lives in the space between science and the clinic: a space that has no owner, no defined handover, and no tolerance for the ad-hocism that research environments not only permit but often thrive on. Research and GMP manufacturing operate on incompatible logics; in a laboratory, variability is a result; in a GMP facility, it is a deviation with regulatory consequences. Researchers optimise for efficacy. Regulators require consistency, traceability, and comparability. The gap between those two imperatives is the translation gap.
The decisions that determine whether a therapy survives that crossing are rarely made at the point of transition. They are made years earlier, at cell line selection, at starting material qualification, at the moment someone chooses a research-grade material because it is available, affordable, and sufficient for the immediate question, without asking what it will take to qualify a GMP-grade equivalent at clinical scale. By the time those decisions reveal their consequences, reversing them is no longer process optimisation. It is programme risk.
This is where a manufacturing partner becomes something other than a service provider. A CDMO that carries genuine regulatory literacy into early-stage partnerships does not simply execute a protocol, it translates. Between the logic of discovery and the logic of GMP. Between what the science requires and what the regulator will accept. Between what works at the bench and what will hold across years of commercial production. In an era when the entire ATMP field is under pressure to prove that its science can become medicine at scale, that distinction is increasingly what separates the programmes that reach patients from the ones that remain merely elegant science.
The question then becomes what that capability actually looks like in practice and what distinguishes a partner built for it from one that has merely adopted it.
What separates a manufacturing partner from a manufacturing service provider?
The capabilities that determine whether a programme survives contact with commercial reality
A CDMO operating within Sweden’s ATMP ecosystem inherits something that cannot be replicated by capability alone. Sweden did not arrive at the frontier of cell and gene therapy by chance. It got there by treating manufacturing infrastructure, regulatory competence, and clinical delivery not as downstream concerns, but as foundational investments, built in parallel with the science, not bolted on after it.
The process is the product, and in ATMP manufacturing, that distinction carries weight that is easy to underestimate early and impossible to ignore later. A therapy that struggles to survive the translation from development to GMP-compliant production loses more than time. It loses momentum, optionality, and often investor confidence. This is what separates a manufacturing partner from a manufacturing service provider. One is architected for commercial reality from the first batch. The other is retrofitted for it, expensively, and often too late. The market has begun to reflect this. Regulatory and QA support services are forecast to expand at a 25.19% growth through 2030, the fastest-growing segment in the CDMO service landscapei, a premium the field is paying for competence it needed earlier. For any programme with serious commercial ambitions, CMC depth and embedded regulatory support are not differentiators. They are the foundation.
What the field requires is a partner whose processes, teams, and infrastructure were built for GMP from the outset, one that can qualify facility upgrades, absorb platform technologies, and transfer complex processes without losing fidelity at each transition. Supply chain agility, material qualification, and critical process parameter adaptation are not secondary concerns. They run in parallel. For allogeneic mammalian therapies, that combination of flexibility and manufacturing maturity is uncommon. What determines programme success is speed of decision-making, depth of process knowledge, and a partner invested in the outcome, one that operates fluently between the investigator’s world and the regulator’s expectations.
The road to scale: autologous heterogeneity is patient derived. Allogeneic heterogeneity is process derived
The case for allogeneic is compelling, but it would be disingenuous to make it without acknowledging what remains unresolved. The challenges are real, and the most consequential of them is biological in nature. Inherent heterogeneity in autologous therapies, the “problem” we worked so hard to engineer away with off-the-shelf therapies, does not so much disappear as relocate. Scale has a way of introducing its own heterogeneity, one that is neither inherent nor desirable, but process-induced and accumulated. Allogeneic platforms are not immune. Passage-related changes, subclonal selection, genomic instability, editing heterogeneity, and differentiation batch effects can all conspire to introduce variance that no master cell bank was designed to carry.
The irony is not lost on anyone working at the intersection of cell biology and commercial manufacturing. The biological variability we celebrated as a feature, and for the most part it is, can, under the pressures of industrial scale, become a manufacturing bug. Which is precisely why the argument for allogeneic does not end with the science. It begins with the discipline required to protect it.
It started with a single patient. In 2014, a child with leukaemia received one of the first CAR-T treatments in a European clinical trial. A decade later, the science is no longer the limiting factor; the ability to manufacture, scale, and deliver these therapies reliably is.
References
[i] Cell Therapy Biomanufacturing Market, Global Forecast 2026–2032, Research and Markets, researchandmarkets.com
[ii] Mendus Announces Start of VITAL-CML Trial. Clinical programme announcement C-MYC / University of Bergen.,2026.
[iii] Allogeneic CD19‑targeted CAR‑T therapy in refractory systemic lupus erythematosus,” Nature family journal, 2025.
[iv] Prospects for Development and Commercialisation of Allogeneic CAR‑Based Therapies for Autoimmune Disease, Transplantation and Cellular Therapy, 2025.